Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
1. IDEAYA enters an exclusive license agreement with Servier for darovasertib. 2. IDEAYA receives $210 million upfront and potential $320 million in milestones. 3. Collaboration aims at developing darovasertib for uveal melanoma globally. 4. FDA designated darovasertib for breakthrough and orphan drug status. 5. Collaborative trials targeting significant unmet needs in rare eye cancer.